MRC1 and neoplasm: High tumor mutational burden, the presence of mismatch repair protein (MMR) deficiency or of microsatellite instability, the estimate of tumor infiltrating lymphocytes (TILs), and the immunohistochemical analysis of PD-L1 expression on tumor cells and immune cells of the microenvironment are used as biomarkers for selecting patients receiving ICIs therapy [16].